H.C. Wainwright 維持對Phasebio Pharmicals(PHAS)的買入評級
TipRanks2022/08/15 06:20 (美東)
Needham將PhaseBio Pharmicals的目標股價從10美元下調至每股8.00美元
道瓊斯2022/08/15 04:42 (美東)
PhaseBio Pharmicals 維持在尼德姆的買入水平
道瓊斯2022/08/15 04:42 (美東)
Needham維持對PhaseBio Pharmicals的買入,將目標股價下調至8美元
Benzinga Real-time News2022/08/15 04:34 (美東)
Phasebio Pharmicals(PHAS)獲得尼德姆的買入評級
TipRanks2022/08/12 16:25 (美東)
分析師提供有關醫療保健公司的見解:Knight Therapeutics(OtherkHTRF)和Phasebio Pharmicals(PHAS)
TipRanks2022/08/12 16:25 (美東)
暫無數據
暫無數據